Oncology – Page 5

Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results

By MedXY 01/09/2026

The final TROPION-Breast01 analysis confirms datopotamab deruxtecan's superior progression-free survival over chemotherapy in HR+/HER2- breast cancer. While overall survival did not reach significance, likely due to subsequent ADC crossover, the drug maintains a favorable safety profile and clinical utility.

news Oncology

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

By MedXY 01/09/2026

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-free survival and a manageable safety profile.

news Oncology Respiratory

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial

By MedXY 01/09/2026

The final analysis of the Phase III ALEX trial confirms alectinib's superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the first-line standard of care for ALK-positive advanced non-small cell lung cancer.

news Oncology

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

By MedXY 01/09/2026

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer compared to standard initiation protocols.

news Oncology Urology

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

By MedXY 01/09/2026

The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven therapy.

news Oncology

National Expertise and Molecular Profiling Extend Survival in Cancer of Unknown Primary: Insights from the French CUP MTB

By MedXY 01/09/2026

A French national study demonstrates that molecularly-guided treatments, facilitated by a dedicated multidisciplinary tumour board, significantly improve survival for patients with cancer of unknown primary, extending median overall survival from 11.0 to 18.6 months compared to empiric therapy.

news Oncology Pathology & Lab Medicine

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

By MedXY 01/09/2026

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression, identifying superior combination regimens for specific genomic subgroups.

Gastroenterology news Oncology

AXL: The Double-Edged Sword in Colorectal Cancer Treatment

By MedXY 01/09/2026

Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunotherapy, paving the way for more personalized oncology.

Clinical Updates news Oncology Pathology & Lab Medicine

Low-Pass Whole Genome Bisulfite Sequencing for ctDNA Monitoring in Metastatic Colorectal Cancer: Insights from the VALENTINO Trial

By MedXY 01/08/2026

This review evaluates the clinical utility of METER, a novel lp-WGBS workflow for ctDNA detection in RAS wild-type mCRC, demonstrating its prognostic value and cost-effectiveness in monitoring treatment response.

news Oncology

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

By MedXY 01/08/2026

The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resource-constrained healthcare settings.

Gastroenterology news Oncology

Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer

By MedXY 01/08/2026

The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with significantly improved outcomes, establishing a new standard for precision oncology.

news Oncology

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

By MedXY 01/08/2026

The CITRINE trial demonstrates that adding adjuvant carboplatin to standard chemotherapy significantly improves survival in high-risk triple-negative breast cancer patients, primarily by preventing early recurrence.

Gastroenterology news Oncology

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation

By MedXY 01/08/2026

A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumor microenvironment or improve clinical outcomes.

Clinical Updates news Oncology

Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC: Efficacy, Safety, and the Challenges of Combination Therapy in DESTINY-Lung03

By MedXY 01/08/2026

This review analyzes the Phase 1b DESTINY-Lung03 trial results, highlighting the robust efficacy of trastuzumab deruxtecan monotherapy in HER2-overexpressing NSCLC and the prohibitive toxicity encountered when combined with durvalumab and platinum-based chemotherapy.

Gastroenterology news Oncology

Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity

By MedXY 01/08/2026

Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and synergizes with PD-1 inhibitors to convert immunologically 'cold' tumors into 'hot' responsive environments.

news Oncology Urology

Integrating Local and Metastasis-Directed Therapies Redefines Survival in Oligometastatic Prostate Cancer: Evidence from an Umbrella Review

By MedXY 01/08/2026

An umbrella review of 21 meta-analyses involving 160,000 patients confirms that prostate radiotherapy and metastasis-directed therapy significantly improve survival and progression control in oligometastatic prostate cancer, establishing a new multimodal standard of care.

news Oncology Public Health

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

By MedXY 01/08/2026

A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for addressing racial disparities in cancer outcomes.

Gastroenterology news Oncology

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

By MedXY 01/08/2026

A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of clinical benefit.

AI news Oncology

AI-Derived Sarcopenia Metrics Predict Survival Benefit from Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer

By MedXY 01/08/2026

A deep learning analysis of the PanaMa trial reveals that the benefit of adding panitumumab to maintenance therapy for RAS wild-type mCRC is significantly higher in patients with a high muscle-bone ratio, suggesting a new AI-driven approach to personalized oncology.

AI news Oncology

Muscle-Bone Ratio: A New AI-Driven Biomarker for Anti-EGFR Response in Metastatic Colorectal Cancer

By MedXY 01/08/2026

A deep learning-derived sarcopenia marker, the muscle-bone ratio (MBR), has been shown to predict the efficacy of anti-EGFR maintenance therapy in patients with RAS wild-type metastatic colorectal cancer, potentially identifying those who truly benefit from treatment intensification.